Physician profile
Junaid Nasir
NPI 1972850055
$480.80
in general payments reported to CMS, 2019-2025
8 companies · $49.07 in 2025
The $49.07 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.43 · 2021: $11.42 · 2022: $157 · 2023: $106 · 2024: $107 · 2025: $49.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $189.66 | 2022-2023 | Velphoro |
| Novartis Pharmaceuticals Corporation | $135.80 | 2024-2025 | |
| Nxstage Medical, INC. | $49.43 | 2019 | |
| Calliditas Therapeutics US INC. | $33.61 | 2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $21.24 | 2023 | Jynarque |
| Lilly USA, LLC | $20.32 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $19.32 | 2022 | |
| Akebia Therapeutics INC | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.